Jiangxi Rimag Group Names Imaging Expert Meng Tao as Non-Executive Director

An update from Jiangxi Rimag Group Co., Ltd. Class H ( (HK:2522) ) is now available.

Jiangxi Rimag Group has nominated medical imaging specialist Meng Tao as a non-executive director for its second board term, with his appointment to take effect upon approval at an upcoming general meeting. Meng, a former physician at Fudan University’s Zhongshan Hospital and senior clinical expert at Siemens Healthineers China, will also join the board’s audit committee, reinforcing the group’s governance and sector expertise without introducing conflicts of interest.

The company noted that Meng previously led training at its Imaging Academy and has served as a director of Rimag Cloud Medical Technology since early 2024, underscoring his familiarity with the group’s operations and strategic focus. His annual remuneration will be RMB120,000, set with reference to market levels and his responsibilities, and the appointment signals Rimag’s intent to deepen professional oversight as it develops its medical imaging and cloud healthcare businesses.

The most recent analyst rating on (HK:2522) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.

More about Jiangxi Rimag Group Co., Ltd. Class H

Jiangxi Rimag Group Co., Ltd. is a mainland Chinese medical technology group focused on imaging and cloud-based healthcare solutions, operating through units such as Rimag Cloud Medical Technology (Beijing) Co., Ltd. The company provides imaging-related clinical, training, and technology services for hospitals and medical institutions, positioning itself within the fast-growing medical imaging and health-tech segment in China.

Average Trading Volume: 9,686,397

Technical Sentiment Signal: Sell

Current Market Cap: HK$2.39B

For a thorough assessment of 2522 stock, go to TipRanks’ Stock Analysis page.